Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05315167 | A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 267 | Zhuhai Yufan Biotechnologies Co., LtdINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06276868 | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | recruiting | Phase 2 | 71 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 |
| NCT06737250 | NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL(POTENTIAL-P) | recruiting | Phase 2 | 33 | NOBO MedicineINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05859750 | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 78 | AkesoINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06440057 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 78 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06467617 | Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | recruiting | Phase 2 | 35 | Beijing Chest Hospital, Capital Medical UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06558227 | Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 90 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06725121 | Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant(MacroTrans) | recruiting | Phase 1 / Phase 2 | 48 | University Health Network, TorontoOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06734182 | Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer(neovision) | recruiting | Phase 2 | 25 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735326 | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | recruiting | Phase 2 | 105 | Qilu Hospital of Shandong UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735495 | CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors | recruiting | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT04278287 | Chemoradiotherapy in Unresectable Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05934513 | A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 95 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06083207 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 116 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT06636981 | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial | recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06733948 | ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05668962 | Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06242418 | CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)(REVISE) | recruiting | Phase 2 | 60 | West China HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06516289 | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | recruiting | Phase 2 | 130 | Fudan UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05665140 | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients(ELIAS) | recruiting | Phase 2 / Phase 3 | 100 | University Hopsital Schleswig Holstein Campus LübeckOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06727630 | A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma | recruiting | Phase 1 / Phase 2 | 40 | Zhuhai Yufan Biotechnologies Co., LtdINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06728852 | Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study(Vigor) | recruiting | Phase 2 | 32 | Li-kun ChenOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06725498 | Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC | recruiting | Phase 2 | 50 | Beijing Tongren HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02185443 | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases | recruiting | Phase 2 | 43 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma(CARTHEDRALL) | recruiting | Phase 1 / Phase 2 | 81 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05185739 | Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)(PRIMER-1) | recruiting | Phase 2 | 60 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06721286 | Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT05918445 | PM8002 in the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 380 | Biotheus Inc.INDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06482086 | Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer | recruiting | Phase 2 | 75 | West China HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06718205 | Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 112 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06718309 | Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC | recruiting | Phase 2 | 40 | First People's Hospital of HangzhouOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04861584 | Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | recruiting | Phase 2 | 41 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06341400 | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | recruiting | Phase 1 / Phase 2 | 55 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06172595 | FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma(FET PET in HGG) | recruiting | Phase 2 | 22 | Singapore General HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06603402 | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC | recruiting | Phase 2 | 41 | Sichuan UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06714383 | Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma | recruiting | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06112704 | HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors | recruiting | Phase 2 | 220 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06401005 | SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) | recruiting | Phase 2 | 51 | Hubei Cancer HospitalOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06444009 | A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 90 | Lei LiuOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06582628 | Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)(TEAM PC) | recruiting | Phase 2 | 78 | Fundacion OncosurNETWORK | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05475613 | Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation | recruiting | Phase 2 | 59 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06405139 | Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709417 | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709885 | HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer | recruiting | Phase 2 | 100 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05891561 | Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | recruiting | Phase 2 | 120 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | recruiting | Phase 2 | 74 | Anhui Provincial Cancer HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06708858 | Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer | recruiting | Phase 2 | 35 | Dai, GuanghaiOTHER | 1 | Nov 27, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Dec 17, 2024source: clinicaltrials